World HBV Therapeutics Marketplace Canvassed in In-demand GlobalData Report Published at MarketPublishers.com
18 Apr 2016 • by Natalie Aster
LONDON – Despite the presence of effective prophylactic vaccines, chronic hepatitis B virus (HBV) infection remains a severe global health concern, with estimated more than 350 million people worldwide currently having this illness. Additionally, patients with chronic hepatitis B are at high risk for life-threatening complicating disorders including liver cirrhosis and malignant hepatoma.
The HBV therapeutics market across the 8 major pharma markets (the US, Germany, France, Spain, Italy, Japan, the UK, and China) is poised to expand from close to USD 2.4 billion in 2014 to USD 3 billion by 2024-end, posting a CAGR of 2.4%. The growth will mainly be propelled by the introduction of pipeline agents, specifically those with novel modes of action (MoA), whilst rapid generic erosion across the markets in question is anticipated to restrain the market’s growth in the foreseeable future.
Whilst pipeline agents hold the potential to address a number of the unmet needs in HBV disease, more clinical information is required to show their primacy over the existing therapies. Furthermore, these agents have pioneered new treatment modes, which retain considerable room for future development.
A slew of opportunities lying in the development of antiviral medicines with new MoAs, which can enhance the efficacy of current drug products, will exist for existing and future players in the HBV therapeutic universe in the years to come.
Insightful research report “PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024” prepared by GlobalData offers an all-round, detailed examination of the HBV infection therapeutics marketplace. It provides data on the sales of HBV-specific drugs in patients aged 18 years and above in the 8MM. The study takes a careful look at the disease; provides estimates and forecasts of the market revenues during 2014-2024, including details about the annual cost of therapy (ACoT) and key pipeline product sales over the period. It gives a strategic assessment of top competitors in the industry, covers the unmet needs, evaluates the pipeline universe, and offers a market outlook for HBV therapeutics. A thorough pipeline analysis is included. The report casts light on the key industry drivers, limiters and challenges. The competitive scenario, current and prospective, in the worldwide HBV therapeutics market is canvassed in the report as well.
More studies by our market research partner can be found at GlobalData page.